ASD presents with a wide range of symptoms—but many stem from shared biological disruptions like oxidative stress, mitochondrial dysfunction, and imbalanced neurotransmitter signaling. RT0307 was built to target these interconnected drivers, with the goal of improving how individuals with autism think, process, and respond to the world around them.
This biology-first approach aims to unlock functional gains in cognition, communication, and sensory engagement—without the tradeoffs of sedation or emotional blunting seen in traditional treatments.
RT0307 is a novel, small molecule that addresses the three biological drivers of autism:
RT0307 is designed to improve quality of life by supporting cognitive clarity, emotional stability, and meaningful daily engagement—without masking personality or behavior.
The biological drivers targeted by RT0307—oxidative stress, neurotransmitter imbalance, and mitochondrial dysfunction—are common across multiple conditions that affect cognitive clarity and executive function.
While RT0307 is purpose-built to improve cognition, and adaptive behavior in autism, its mechanism makes it a promising candidate for other high-need areas. These include mild neurodegenerative disorders, where similar disruptions in energy metabolism and brain signaling are at play.
